Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: A pilot study

Leukemia and Lymphoma

Volumn 42, Issue 5, 2001, Pages 1033-1041

  Lhomme C ^a   Brault, PH ^a   Bourhis, J H ^a   Pautier, P ^a   Dohollou, N ^a   Dietrich, P Y ^a   Akbar Zadeh, G ^a   Lucas, C ^a   Pico, J L ^a   Hayat, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Gonadotropin releasing hormone agonist; Menstruation; Progestins; Thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN AGONIST; LEUPRORELIN; NOMEGESTROL ACETATE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HEMATOMA; HORMONAL THERAPY; HUMAN; LEG PAIN; LEUKEMIA; LIVER TOXICITY; LYMPHOMA; MENSTRUATION DISORDER; METRORRHAGIA; MYELOMA; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SUBCUTANEOUS NODULE; SUSTAINED RELEASE FORMULATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VAGINA BLEEDING;

EID: 0034852229     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097723     Document Type: Article

References (35)

1. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation
2. Assessment of medical treatments for menorrhagia
3. Leuprolide acetate: Applications in gynecology
4. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer
5. Long-term use of an LH-RH Agonist in the management of uterine leiomyomas: A study of 17 cases
6. LH-RH analogs in gynecological oncology: A review
7. Efficacy and safety of leuprorelin acetate depot for prostate cancer in a long-term follow-up study: Preliminary results
8. Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostate cancer patients
9. GnRH Agonists and antagonists. Current clinical status
10. Gonadotrophin - Releasing Hormone Agonist. A guide to use and selection
11. Le traitement des pubertés précoces centrales par la triptoréline à libération prolongée
12. Timing of initiation and dose schedule of leuprolide influence the time course of ovarian suppression
13. Management of infection in patients with acute leukemia
14. Liver damage from low-dose oral contraceptives
15. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis
16. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation
17. Clinical use of oral contraceptives administered vaginally: A case report
18. Development and clinical evaluation of double-phased suppositories of progesterone with subtained release property
19. Controlled release contraceptive devices: A status report
20. Luteinizing hormone-releasing hormone analogue: Leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation
21. Control of hypermenorrhea in female patients with severe thrombocytopenia with a special relevance to the efficacy of LH-RH analogue
22. Direct effects of gonatotropin-releasing hormone on the ovary in rats and humans
23. The agonist (d-leu-6, des-gly-10)-LHRH-ethylamide does not protect the fecundity of rats exposed to high dose unilateral ovarian irradiation
24. Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: Preliminary observations
25. Failure to preserve fertility in patients with Hodgkin's disease
26. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy
27. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial
28. Gonadotropin-releasing hormone agonists: Strategies for managing the hypoestrogenic effects of therapy
29. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis
30. Leuprolide acetate and bone mineral density measured by quantitative digitized radiography
31. Steroidal and nonsteroidal "add-back" therapy: Extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient
32. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
33. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation
34. The nasal delivery of systemic drugs